Genovac is an approved contract research provider with all leading transgenic animal companies.
Genovac is the leader in the use of transgenic animal platforms for the generation of fully human, monoclonal antibodies and can assist you in accelerating the development of therapeutic antibodies. The company offers several options for your projects.
OmniAb™ Antibody Discovery
Genovac combines its Antibody Technology with Ligand’s OmniAb™ transgenic rodents for superior human antibody development.
Human Antibodies from Genovac and Ligand Pharmaceutical
Partnering for best-in-class discovery and development services
Combining Genovac Antibody Technology with Ligand’s OmniAb™ transgenic rodents provides clients with accelerated discovery, in vivo optimization for therapeutic efficacy and manufacturability, and fully human sequences for safety and reduced immunogenicity.
A variety of immunization protocols have been applied successfully with OmniAb animals, including DNA, peptide, protein, or cell immunization.The technology also has been used to complete multiple projects with OmniRat™, OmniFlic™ and OmniMouse™ antibody platforms.
By establishing a collaborative workflow between the end user, Ligand and the breeding facility, Genovac can take a project from a target sequence to immunization, fusion, screening and delivery of the desired antibody.
Project Deliverables
Genovac delivers hybridoma and/or B cells for every antibody project. It also provides the following complementary services:
Target Analysis
Complete our online form for a complimentary antibody target analysis.
Human Antibodies from Genovac and Trianni, Inc.
Expressing full human antibodies for therapeutic discovery
The Trianni MouseTM embodies powerful, next-generation platform technology enabling efficient generation of fully-human monoclonal antibodies. This transgenic mouse carries a complete human antibody repertoire, including highly engineered versions of all three antibody-encoding genetic loci (Heavy, Kappa, and Lambda), in a single organism.
Generated using state-of-the-art DNA synthesis and genome modification methodology, Trianni mice take advantage of processes that “screen” antibodies for heavy chain and light chain compatibility, robust expression and target selectivity in vivo.
Importantly, only the exons encoding the variable-domain sequences in the mouse have been replaced by their counterpart human exon sequences. All of the remaining Ig sequence is of mouse origin, including promotor, enhancer and other regulatory elements. Fully-human therapeutics can be generated from resulting chimeric repertoires through standard cloning methodology.
Objective: Generate a diverse panel of mAbs specific for different members of the human CEACAM family in the OmniRat Antibody Platform.
Target: Human CEACAM5
Method: Genetic Immunization of OmniRats
Result: Similar epitope coverage of cross-reactive mAbs with OmniRats and Wistar
Objective: Generating monoclonal antibodies using the OmniRat Antibody Platform against the human TCR-complex with cross reactivity to the Cynomolgus TCR-complex.
Method: Genetic immunization of OmniRats by co-immunization with CD3 chains.
The TCR–complex is composed of 6 different polypeptides on the surface of T-cells:
Conclusions
Good anti-protein complex-specific response, antigen-dependent strain response, multi-plexed for complex-only selection.
Conclusions
Good anti-GPCR response, antigen-dependent strain response, multi-plexed, cross-reactive, real-time screening, titer not linear predictor of specific antibody yield.
Hybridoma and/or B cells are delivered for every antibody project. We also provide the following complementary services:
Complete our online form for a complimentary antibody target analysis.
